Drug-discovery company Evotec and biotech Odyssey Therapeutics have formed a partnership to use artificial intelligence to find new treatments for autoimmune and inflammatory diseases.
Announced August 7, 2026, the collaboration combines Evotec’s data-driven discovery platform — AI data science, advanced screening, compound libraries and disease-modeling tools (including stem-cell-based and multi-omics approaches) — with Odyssey’s expertise in the biology of immune-driven diseases. The goal is to speed the discovery and validation of small-molecule drug candidates.
How the deal is structured
Evotec may receive milestone payments when it delivers validated “hit series” — promising early drug candidates — for the targeted diseases. Specific financial terms were not disclosed. “Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches,” said Evotec chief scientific officer Cord Dohrmann.
Part of a pattern
The deal is one of many pairing AI-and-data platforms with disease-focused biotechs, as the industry bets that blending computation with biology can shorten the slow, failure-prone early stage of drug discovery. Evotec separately noted that Niagen Bioscience picked it to advance a small-molecule candidate for rare genetic diseases and accelerated aging.